Wave Life Sciences
WVE-006, a GalNAc-conjugated AIMer for AATD, is the modality's lead asset; RestorAATion-2 data (May 2026) showed 64% wild-type M-AAT, a 71% reduction in toxic Z-AAT, 11.9 µM total AAT on 200 mg biweekly dosing (13.6 µM on 400 mg monthly), and editing sustained at least three months after the last dose,…
- Country
- United States
- Ticker
- NASDAQ:WVE
AATD editor (WVE-006)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| RNA editing (ADAR) therapeutics | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.